πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 29,054 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12391643

Substituted amino-thiol and amino-disulfide compounds, and uses thereof

The Regents of the University of California Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391686

Compounds and uses thereof

FOGHORN THERAPEUTICS INC. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391642

Tetrahydro-1H-cyclopenta[cd]indene derivatives as hypoxia inducible factor-2(alpha) inhibi

NIKANG THERAPEUTICS, INC. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12390497

Microbial strains for virus inhibition

MICROBIAL DISCOVERY GROUP, LLC Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12390512

Depolymerase capable of degrading extracellular polymeric substances of Klebsiella pneumon

SHANGHAI REINOVAX BIOLOGICS CO., LTD Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12390427

Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12390453

Method for reducing side effects from administration of phosphodiesterase-4 inhibitors

ARCUTIS BIOTHERAPEUTICS, INC. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12390462

Muscarinic acetylcholine M1 receptor antagonists

Contineum Therapeutics, Inc. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12390463

Dosage forms and regimens for amino acid compounds

Pliant Therapeutics, Inc. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12389931

Oyster peptide with effect of improving sexual function and preparation method thereof

CHINA NATIONAL RESEARCH INSTITUTE OF FOOD & FERMENTATION INDUSTRIES CO., LTD. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12390483

Compounds and methods for treating neurological and cardiovascular conditions

The Board of Regents of the University of Texas System Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391920

Models of tauopathy

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391750

Anti-C1S antibodies and methods of use thereof

Bioverativ USA Inc. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391753

Antigen binding molecule formats

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391742

Anti-KRAS-G12D T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391923

SIRPΞ±-silenced natural killer (NK) cells

The Regents of the University of California Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391663

Isoindolinone compounds

Monte Rosa Therapeutics AG Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391760

Method of treating primary sclerosing cholangitis

Takeda Pharmaceutical Company Limited Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12390496

Methods for treating ulcerative colitis

Finch Therapeutics Holdings LLC Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12391765

Methods and materials for assessing response to plasmablast- and plasma cell-depleting the

Takeda Pharmaceutical Company Limited Β· Granted Tue Aug 19 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 14 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12384854

Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema

Takeda Pharmaceutical Company Limited Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12383503

Adagrasib solid pharmaceutical compositions

Mirati Therapeutics, Inc. Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12384830

Compositions and methods for improving immunotherapy

Regents of the University of Minnesota Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12384829

Pocket engineering of HLA alleles for treating autoimmunity

The Regents of the University of Colorado, a Body Corporate Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted